{"product_id":"new-treatments-for-fatty-liver-disease-and-alcohol-related-liver-disease-a-patients-guide-to-the-science-behind-the-clinical-trials","title":"New Treatments for Fatty Liver Disease and Alcohol-Related Liver Disease: A Patient's Guide to the Science Behind the Clinical Trials","description":"\u003cp\u003eNon-alcoholic fatty liver disease (NAFLD) and alcohol-related liver disease (ALD) are two of the most common chronic liver diseases worldwide, and together they have become the leading reasons for liver transplantation. This review article explains how scientists have dramatically advanced their understanding of these diseases, paving the way for more than 100 clinical trials testing new treatments. The authors — liver specialists from the Icahn School of Medicine at Mount Sinai in New York — describe promising drug candidates that target inflammation, fat accumulation, and scarring (fibrosis) in the liver, and emphasize that successful treatments will require close collaboration between academic researchers and pharmaceutical companies.\u003c\/p\u003e\n\n\u003ch1\u003eNew Treatments for Fatty Liver Disease and Alcohol-Related Liver Disease: A Patient's Guide to the Science Behind the Clinical Trials\u003c\/h1\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n  \u003cli\u003e\u003ca href=\"#background\"\u003eUnderstanding NAFLD and ALD: Two Diseases, Many Similarities\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#nash-interest\"\u003eWhy Is There So Much Interest in NASH?\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ald-focus\"\u003eWhy the Heightened Focus on Alcohol-Related Liver Disease?\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#learned\"\u003eWhat Have Researchers Learned From Clinical Trials So Far?\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#targets\"\u003eEmerging Treatments: An Overview of Therapeutic Targets\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ppar\"\u003ePPAR-Targeting Drugs\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#thrb\"\u003eThyroid Hormone Receptor-Beta Agonists\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#bile-acids\"\u003eBile Acid Pathways as a Treatment Target\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#implications\"\u003eClinical Implications: What This Means for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#limitations\"\u003eStudy Limitations: What This Review Could Not Prove\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#recommendations\"\u003eRecommendations for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eNAFLD and ALD are now the most common reasons for liver transplantation in the United States.\u003c\/li\u003e\n\u003cli\u003eOver 100 clinical trials for NASH are underway, testing drugs that target fat, inflammation, and fibrosis.\u003c\/li\u003e\n\u003cli\u003eIn a meta-analysis of 39 trials, 25% of placebo patients improved NASH activity, making drug efficacy harder to prove.\u003c\/li\u003e\n\u003cli\u003eThyroid hormone receptor-beta agonists like MGL-3196 and VK2809 reduced liver fat substantially in 12–36 week trials.\u003c\/li\u003e\n\u003cli\u003eAlcohol abstinence is the most effective therapy to reverse alcohol-related liver disease; only corticosteroids and transplantation are approved for alcoholic hepatitis.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"background\"\u003eUnderstanding NAFLD and ALD: Two Diseases, Many Similarities\u003c\/h2\u003e\n\n\u003cp\u003eNon-alcoholic fatty liver disease (NAFLD) and alcohol-related liver disease (ALD) are very common forms of chronic liver disease around the world. Both are linked to a rising number of deaths from all causes — not just liver-related deaths. While they are distinct diseases with different triggers, NAFLD and ALD share striking similarities. Both can lead to fatty liver, inflammation of the liver (steatohepatitis), and the development of scar tissue (fibrosis). Over time, both can progress to cirrhosis and its complications, including liver cancer (hepatocellular carcinoma, or HCC).\u003c\/p\u003e\n\n\u003cp\u003eWhen a patient has both conditions at the same time, the disease progresses even faster. Together, NAFLD and ALD are now the most common reasons for liver transplantation in the United States. They share several underlying biological pathways, including the buildup of fat in liver cells (hepatic steatosis), inflammation, and the activation of cells that produce scar tissue.\u003c\/p\u003e\n\n\u003ch2 id=\"nash-interest\"\u003eWhy Is There So Much Interest in NASH?\u003c\/h2\u003e\n\n\u003cp\u003eTwo epidemics are driving the urgency: obesity and NAFLD. In the United States, NAFLD — which includes both simple fatty liver (non-alcoholic fatty liver, or NAFL) and the more aggressive form, non-alcoholic steatohepatitis (NASH) — affects an estimated 65 to 90 million adults. That represents roughly \u003cstrong\u003e20–30% of the entire U.S. population\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eNASH is the progressive form of the disease. It is defined by the presence of inflammation and damage to liver cells (hepatocytes), and it is typically accompanied by fibrosis and, eventually, cirrhosis. NASH has been recognized as a leading cause of liver cancer (HCC), and experts believe it is likely to become the most common reason for liver transplantation in the coming years.\u003c\/p\u003e\n\n\u003cp\u003eSome key numbers help explain the scale of the problem:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eNASH accounts for about \u003cstrong\u003e20–30% of the NAFLD population\u003c\/strong\u003e.\u003c\/li\u003e\n  \u003cli\u003eOf those with NASH, \u003cstrong\u003e4–6% can progress to cirrhosis\u003c\/strong\u003e — though this is likely an underestimate because the disease is not easily diagnosed.\u003c\/li\u003e\n  \u003cli\u003eNASH is typically \u003cstrong\u003easymptomatic\u003c\/strong\u003e (producing no symptoms), and up to \u003cstrong\u003e30% of affected patients have completely normal liver enzymes\u003c\/strong\u003e on routine blood tests.\u003c\/li\u003e\n  \u003cli\u003eThe prevalence of NASH in the United States is projected to grow from \u003cstrong\u003e20% to 27% between 2015 and 2030\u003c\/strong\u003e.\u003c\/li\u003e\n  \u003cli\u003eBy that time, \u003cstrong\u003e20% of NASH cases are expected to have advanced fibrosis or cirrhosis (stage F3\/F4)\u003c\/strong\u003e, which is associated with accelerated disease, a higher risk of both liver-related and non-liver-related death, and a growing economic burden.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eWhy the sudden flood of interest from drug companies? A major reason is the success of hepatitis C treatments. Direct-acting antiviral agents now cure more than 95% of chronic hepatitis C infections, and aggressive global efforts aim to eliminate hepatitis C by 2030. This success has freed up pharmaceutical and biotechnology companies to redirect their drug development efforts toward NASH and its associated fibrosis.\u003c\/p\u003e\n\n\u003cp\u003eThe article notes that there are now \u003cstrong\u003eover 100 registered clinical trials for NASH\u003c\/strong\u003e in various phases of development. Companies with successful track records in viral hepatitis have pivoted toward NASH, and companies with programs in cardiometabolic disease are leveraging the strong connections between NASH, obesity, and type 2 diabetes (T2DM). Because the stage of liver fibrosis is strongly associated with both liver-related and all-cause death, anti-fibrotic drugs — regardless of the underlying cause of liver disease — are also emerging rapidly as a treatment strategy.\u003c\/p\u003e\n\n\u003ch2 id=\"ald-focus\"\u003eWhy the Heightened Focus on Alcohol-Related Liver Disease?\u003c\/h2\u003e\n\n\u003cp\u003eAlcohol-related liver disease covers a spectrum of conditions, from alcoholic steatosis (fatty liver) to alcoholic steatohepatitis (ASH) and advanced ALD characterized by alcoholic hepatitis (AH), cirrhosis, and complications such as hepatic encephalopathy, jaundice, portal hypertension-related problems, and liver cancer.\u003c\/p\u003e\n\n\u003cp\u003eThe true burden of ALD is almost certainly underreported. Patients often hide their alcohol use because of social stigma, and ALD frequently goes undiagnosed when it occurs alongside other chronic liver diseases. The article highlights these sobering statistics:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003eALD accounts for up to \u003cstrong\u003e48% of cirrhosis-related deaths in the United States\u003c\/strong\u003e.\u003c\/li\u003e\n  \u003cli\u003eAlcohol-related mortality remains the \u003cstrong\u003efourth leading preventable cause of death in the U.S.\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003eIn a 2016 report, \u003cstrong\u003eALD was the leading indication for liver transplantation\u003c\/strong\u003e in the United States.\u003c\/li\u003e\n  \u003cli\u003eA 2018 U.S. population-based study demonstrated \u003cstrong\u003eincreasing alcoholic cirrhosis-related deaths in people aged 25 to 34 years\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eAn analysis of the National Health and Nutrition Examination Survey (NHANES) database from 2001 to 2016 found that the overall prevalence of ALD remained stable at 4.3% (95% CI, 3.5–5.0%) to 4.7% (95% CI, 4.2–5.1%) (P=0.69). However, the severity of disease is worsening:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003eThe prevalence of \u003cstrong\u003estage 2 fibrosis increased from 0.6% (95% CI, 0.5–0.8%) to 1.5% (95% CI, 1.3–1.8%)\u003c\/strong\u003e (P\u0026lt;0.001).\u003c\/li\u003e\n  \u003cli\u003eThe prevalence of \u003cstrong\u003estage 3 fibrosis or higher increased from 0.1% (95% CI, 0.02–0.10%) to 0.2% (95% CI, 0.2–0.4%)\u003c\/strong\u003e (P=0.045).\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThese trends point to a growing burden of advanced ALD in the near future. Yet despite the fact that ALD has been recognized for centuries, treatments remain outdated and inadequate. Current recommendations are largely based on studies performed decades ago. Alcohol abstinence remains the most effective therapy to reverse ALD. Early liver transplantation has been effective in selected patients with acute alcoholic hepatitis, offering both short-term and long-term survival benefits — but transplantation is not feasible for the vast majority of ALD patients.\u003c\/p\u003e\n\n\u003ch2 id=\"learned\"\u003eWhat Have Researchers Learned From Clinical Trials So Far?\u003c\/h2\u003e\n\n\u003cp\u003eNASH has a highly variable clinical course. Some patients improve on their own (spontaneous regression), while others progress relentlessly to advanced fibrosis. This variability makes designing clinical trials genuinely difficult.\u003c\/p\u003e\n\n\u003cp\u003eOne of the major obstacles researchers have encountered is the \u003cstrong\u003ehigh placebo response rate\u003c\/strong\u003e in NASH trials. Patients receiving a placebo (an inactive pill) often show improvement, which can make it hard to prove that an experimental drug is actually working. In a recent meta-analysis of \u003cstrong\u003e39 clinical trials\u003c\/strong\u003e, placebo was associated with a 2-point or greater improvement in the NAFLD Activity Score (NAS) in \u003cstrong\u003e25% of patients (95% CI, 21–29%)\u003c\/strong\u003e — with similar results even when the analysis was restricted to patients with no worsening in fibrosis.\u003c\/p\u003e\n\n\u003cp\u003eLikewise:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e30%\u003c\/strong\u003e of placebo-treated patients had at least a 1-point improvement in individual components of the NAS score.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e21%\u003c\/strong\u003e of placebo-treated patients showed improvement in fibrosis stage.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThis high placebo response likely reflects, in part, inadvertent lifestyle changes that patients make when they join a clinical trial. The authors stress that clinical trials should account for this by enrolling patients with more advanced disease, using evolving non-invasive surrogate markers.\u003c\/p\u003e\n\n\u003cp\u003eAnother challenge: proving a drug changes the course of the disease takes time. Detecting a 1-stage change in fibrosis may require up to \u003cstrong\u003e7 years\u003c\/strong\u003e of follow-up. Even if a drug is approved based on improvements seen on liver biopsy, long-term success — and therefore long-term drug approval — will depend on demonstrating that patients actually \u003cem\u003efeel\u003c\/em\u003e, \u003cem\u003efunction\u003c\/em\u003e, and \u003cem\u003esurvive\u003c\/em\u003e better. The U.S. Food and Drug Administration (FDA) has recently issued guidance on NASH clinical trial design that reflects this evolving landscape.\u003c\/p\u003e\n\n\u003cp\u003eThe gold standard for diagnosing NASH remains the \u003cstrong\u003eliver biopsy\u003c\/strong\u003e, despite its limitations: it is invasive, carries risks, and can miss unevenly distributed disease (sampling variability). Researchers are increasingly using surrogate markers and imaging to identify patients and measure improvement, including:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFIB-4\u003c\/strong\u003e and the \u003cstrong\u003eNAFLD fibrosis score\u003c\/strong\u003e — non-invasive blood test-based calculations;\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eVibration controlled transient elastography (VCTE)\u003c\/strong\u003e — an ultrasound-based technique that measures liver stiffness and fat;\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMRI proton density fat fraction (MRI-PDFF)\u003c\/strong\u003e — a precise imaging method to measure liver fat;\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMultiparametric MRI\u003c\/strong\u003e — to detect changes related to inflammation and fibrosis;\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eBlood-based biomarkers\u003c\/strong\u003e such as cytokeratin-18 (CK-18) and the European Fibrosis Panel (ELF).\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eHowever, these non-invasive tools have not yet been validated enough to replace biopsy in late-stage (Phase 2b and Phase 3) trials, which still rely on biopsy-based histological endpoints. Early \"proof-of-concept\" (Phase 2a) studies are typically short — 12 to 16 weeks — making it difficult to show meaningful biopsy improvement. As a result, improvement predicted by non-invasive tests does not always translate into biopsy-confirmed improvement in longer trials.\u003c\/p\u003e\n\n\u003cp\u003eClinical trial design for ALD is even more challenging. The presentation of the disease varies greatly, there are few reliable non-invasive or serological tests for diagnosing and staging it, and patient follow-up is often uneven. Most clinical trials and approved therapies focus on alcoholic hepatitis, the most severe subset. Currently, the only approved treatments are \u003cstrong\u003ecorticosteroids\u003c\/strong\u003e and \u003cstrong\u003eliver transplantation\u003c\/strong\u003e. The endpoints achieved with corticosteroid therapy are typically short-term — 28-day and 6-month mortality — with variable long-term survival benefits.\u003c\/p\u003e\n\n\u003cp\u003eThe article also raises an important ethical point: because corticosteroids are a known effective therapy for alcoholic hepatitis, it is difficult and potentially unethical to design placebo-controlled trials for these patients. Most new therapies for alcoholic hepatitis must therefore be compared against corticosteroids rather than against a placebo, which makes proving a drug's benefit more rigorous and more difficult. Unlike in NASH, where placebo-controlled trials are standard, researchers in ALD use prognostic scoring systems such as the Model for End-Stage Liver Disease (MELD), the age-bilirubin-INR-creatinine (ABIC) score, the Glasgow score, or the Lille score to help evaluate treatment effects. Liver biopsy in alcoholic hepatitis trials is highly controversial — it can help rule out conditions that mimic alcoholic hepatitis (like sepsis), but it carries high risk in very ill or unstable patients.\u003c\/p\u003e\n\n\u003ch2 id=\"targets\"\u003eEmerging Treatments: An Overview of Therapeutic Targets\u003c\/h2\u003e\n\n\u003cp\u003eNASH and ALD are driven by different causes, but they share many clinical, pathological, and histological features. Both involve altered fat metabolism, the death of liver cells (hepatocyte apoptosis), activation of the innate immune system, and activation of hepatic stellate cells (the cells responsible for scar formation). They also each engage unique molecular signaling pathways and dysregulated microRNAs.\u003c\/p\u003e\n\n\u003cp\u003eBased on the underlying biology of NASH, therapeutic targets fall into three categories:\u003c\/p\u003e\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAnti-inflammatory\u003c\/strong\u003e drugs — aimed at reducing liver inflammation;\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAnti-steatotic\u003c\/strong\u003e drugs — aimed at reducing fat accumulation in the liver;\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAnti-fibrotic\u003c\/strong\u003e drugs — aimed at preventing or reversing scar tissue.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eSeveral drugs in clinical trials display more than one of these activities. There is also growing interest in using anti-diabetic medications for NASH, because type 2 diabetes and NASH frequently coexist and diabetes likely contributes to NASH progression. Because even effective drugs only improve NASH in a minority of patients, combination therapies that target multiple disease drivers are increasingly being explored. And given the overlap between NASH and alcoholic steatohepatitis, researchers are also investigating whether drugs developed for NASH could be repurposed for ALD. In practical terms, most agents are being tested first in NASH patients, with the expectation that promising drugs will subsequently be evaluated in ALD.\u003c\/p\u003e\n\n\u003cp\u003eHere is a closer look at several drug targets that are already in late-stage development (Phase 2 and Phase 3 trials).\u003c\/p\u003e\n\n\u003ch2 id=\"ppar\"\u003ePPAR-Targeting Drugs\u003c\/h2\u003e\n\n\u003cp\u003ePeroxisome proliferator-activated receptors (PPARs) are proteins inside cells that act as \"switches\" to turn genes on and off. They are part of a family called nuclear hormone receptors, and they come in three subtypes: \u003cstrong\u003ePPARα\u003c\/strong\u003e, \u003cstrong\u003ePPARγ\u003c\/strong\u003e, and \u003cstrong\u003ePPARβ\/δ\u003c\/strong\u003e. Each plays a crucial role in metabolism:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePPARα\u003c\/strong\u003e reduces triglycerides (blood fats) and regulates energy balance;\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePPARγ\u003c\/strong\u003e increases insulin sensitivity and promotes glucose metabolism;\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePPARβ\/δ\u003c\/strong\u003e has a primary role in fatty acid metabolism.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eThiazolidinediones (TZDs)\u003c\/strong\u003e, which act on PPARγ, are already widely used to treat type 2 diabetes. Studies show they also improve steatosis (fat in the liver), steatohepatitis (inflammation), and hepatic fibrosis. Interestingly, PPARγ drugs appear to work \u003cstrong\u003ebetter in patients who have both NASH and type 2 diabetes\u003c\/strong\u003e than in those with NASH alone — a difference that needs further study. However, TZDs have significant side effects that limit their appeal: weight gain, osteopenia (weakening of bones), peripheral edema (swelling in the legs), and fluid retention.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eElafibranor\u003c\/strong\u003e is a selective \"dual\" PPAR-α\/δ agonist — meaning it activates both PPARα and PPARβ\/δ, but not PPARγ. It is liver-targeted, with little or no activity in skeletal muscle. The PPARα component improves insulin sensitivity and lipid balance by increasing fatty acid oxidation, while the PPARδ component exerts an anti-inflammatory effect. In a post-hoc (secondary) analysis of a Phase 2b trial, elafibranor improved the metabolic features of NASH and showed a favorable cardiometabolic profile. It is currently being tested in a Phase 3 trial called \u003cstrong\u003eRESOLVE-IT (NCT02704403)\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch2 id=\"thrb\"\u003eThyroid Hormone Receptor-Beta Agonists\u003c\/h2\u003e\n\n\u003cp\u003eThyroid hormone receptors (THRs) regulate organ development, growth, differentiation, energy metabolism, and lipid and glucose balance. The \u003cstrong\u003eTHRα\u003c\/strong\u003e subunit is mainly found in the brain, skeletal muscle, and cardiac muscle, and is responsible for many of the classic symptoms of thyroid hormone excess (thyrotoxicosis). The \u003cstrong\u003eTHRβ\u003c\/strong\u003e subunit is found predominantly in the liver, brain, and kidneys, and is mainly responsible for metabolic regulation.\u003c\/p\u003e\n\n\u003cp\u003eBoth subclinical hypothyroidism (mild underactive thyroid) and overt hypothyroidism are more common in patients with NAFLD. Because THRβ is so heavily expressed in the liver, drugs that selectively activate THRβ are attractive candidates for treating metabolic syndrome, NAFLD, and even liver cancer. Human studies have shown that activating THRβ can help break down fatty acids and improve mitochondrial function, reducing \"lipotoxicity\" (injury caused by fats) and significantly lowering LDL (\"bad\") cholesterol, triglycerides, and liver fat.\u003c\/p\u003e\n\n\u003cp\u003eTwo selective THRβ agonists stand out in the article:\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eMGL-3196 (resmetirom).\u003c\/strong\u003e This drug was studied in a 36-week, randomized, double-blind, placebo-controlled Phase 2 trial in patients with NASH. The primary endpoint was reduction in liver fat measured by MRI-PDFF; secondary endpoints included effects on NASH, liver enzymes, indirect fibrosis biomarkers, and blood lipids at weeks 12 and 36. The results were striking:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eLiver fat was reduced by \u003cstrong\u003e36% at 12 weeks and 37% at 36 weeks\u003c\/strong\u003e with the lower dose of MGL-3196;\u003c\/li\u003e\n  \u003cli\u003eWith the higher dose, liver fat fell by \u003cstrong\u003e42% and 49%\u003c\/strong\u003e at the same time points;\u003c\/li\u003e\n  \u003cli\u003ePatients on placebo had only \u003cstrong\u003e8% and 10%\u003c\/strong\u003e reductions.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003ePatients taking MGL-3196 also achieved significant improvements in lipid profile, liver enzymes, and NASH histological (biopsy-based) endpoints compared with placebo. The greatest benefit on NASH endpoints was seen in patients who achieved a ≥30% fat reduction on MRI-PDFF: \u003cstrong\u003e37% of \"MRI responders\" improved versus only 4% of \"MRI non-responders\" (P=0.001)\u003c\/strong\u003e. MGL-3196 is now moving forward into a Phase 3 clinical trial (NCT03900429).\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eVK2809.\u003c\/strong\u003e This is another selective THRβ agonist being evaluated in NASH. In a 16-week Phase 2 randomized placebo-controlled trial, patients with NAFLD were identified by MRI-PDFF showing more than 8% liver fat and LDL cholesterol higher than 110 mg\/dL. The primary endpoint was change in LDL cholesterol, with secondary endpoints including change in liver fat (MRI-PDFF) and effects on other atherogenic lipoproteins (particles that promote artery-clogging plaque). The trial found:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eA significant placebo-adjusted reduction in LDL cholesterol of \u003cstrong\u003e−23.6%\u003c\/strong\u003e in the every-other-day dosing arm and \u003cstrong\u003e−20.2%\u003c\/strong\u003e in the daily arm;\u003c\/li\u003e\n  \u003cli\u003eA dramatic relative reduction in liver fat of \u003cstrong\u003e56.5% (every other day)\u003c\/strong\u003e and \u003cstrong\u003e59.7% (daily)\u003c\/strong\u003e at week 12, compared with only \u003cstrong\u003e8.9%\u003c\/strong\u003e for placebo;\u003c\/li\u003e\n  \u003cli\u003eSignificant reductions in lipoprotein(a) and apolipoprotein B in both VK2809 arms versus placebo.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eVK2809 is planned for a Phase 2B study.\u003c\/p\u003e\n\n\u003ch2 id=\"bile-acids\"\u003eBile Acid Pathways as a Treatment Target\u003c\/h2\u003e\n\n\u003cp\u003eBile acids are synthesized (produced) from cholesterol in liver cells, then secreted into the bile canaliculi along with other components of bile, including water, cholesterol, bilirubin, phospholipids, and inorganic salts. For decades, bile acids were known primarily for their role in cholesterol balance and fat digestion — they act like a natural detergent, emulsifying fats in the small intestine so they can be absorbed.\u003c\/p\u003e\n\n\u003cp\u003eIn more recent years, scientists have discovered that bile acids also function as powerful signaling molecules. They activate two major types of receptors: a nuclear receptor called the \u003cstrong\u003efarnesoid X receptor (FXR)\u003c\/strong\u003e, and a transmembrane (cell-surface) receptor called the \u003cstrong\u003eTakeda G-protein-coupled receptor (TGR5)\u003c\/strong\u003e. These receptors regulate a wide range of metabolic processes, including glucose and lipid metabolism, energy expenditure, and inflammation. This has made bile acid pathways a fertile area for drug development in fatty liver disease, with several FXR agonists advancing through clinical trials for NASH. (The original article's discussion of this section was truncated, but the key concept is that bile acid signaling — particularly through FXR — has become a major focus of NASH drug development.)\u003c\/p\u003e\n\n\u003ch2 id=\"implications\"\u003eClinical Implications: What This Means for Patients\u003c\/h2\u003e\n\n\u003cp\u003eThis review carries several important messages for patients living with — or at risk for — NAFLD and ALD.\u003c\/p\u003e\n\n\u003cp\u003eFirst, \u003cstrong\u003ethe placebo response in NASH trials is real and substantial\u003c\/strong\u003e. In a meta-analysis of 39 trials, a quarter of patients receiving placebo improved their NAS score by 2 points or more, and 21% improved their fibrosis stage. What does this mean for you? Lifestyle changes — even accidental ones — can genuinely improve liver health. The act of joining a trial and receiving regular medical attention appears to motivate diet and exercise changes that have measurable biological effects.\u003c\/p\u003e\n\n\u003cp\u003eSecond, \u003cstrong\u003ethe treatment landscape for NASH is about to change dramatically\u003c\/strong\u003e. With more than 100 registered clinical trials under way, multiple drug candidates are now in Phase 2 and Phase 3 testing. Drugs that selectively activate thyroid hormone receptor beta (MGL-3196, VK2809), dual PPAR agonists (elafibranor), FXR agonists (obeticholic acid), and anti-fibrotic agents are showing meaningful reductions in liver fat — in some cases 40–60% within 12 to 36 weeks — compared with single-digit reductions on placebo. While fat reduction is not the same as curing the disease, it is a strong early signal of efficacy.\u003c\/p\u003e\n\n\u003cp\u003eThird, \u003cstrong\u003ethe field is shifting toward treating fibrosis, not just fat\u003c\/strong\u003e. Because fibrosis stage is the strongest predictor of death in NAFLD, anti-fibrotic drugs are being developed independently of the underlying cause. This means that patients with advanced fibrosis (F3\/F4) may eventually have treatment options even if the fat and inflammation components of their disease have not fully resolved.\u003c\/p\u003e\n\n\u003cp\u003eFourth, \u003cstrong\u003eALD remains a neglected disease with urgent unmet needs\u003c\/strong\u003e. Only two treatments are approved for alcoholic hepatitis (corticosteroids and liver transplantation), and both are limited in their long-term effectiveness. The rising rates of advanced fibrosis in younger age groups (25–34 years) signal a coming wave of alcohol-related cirrhosis. The article calls for regulatory agencies, industry, and clinicians to work together to develop effective pharmacotherapies for ALD, combined with community-based approaches to reduce alcohol dependency.\u003c\/p\u003e\n\n\u003ch2 id=\"limitations\"\u003eStudy Limitations: What This Review Could Not Prove\u003c\/h2\u003e\n\n\u003cp\u003eBecause this is a review article, it does not present new patient data. Instead, it summarizes the state of the science at the time of publication (January 2021). Several important limitations should be kept in mind:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003eThe review cannot establish whether any of the drugs discussed will ultimately be approved. Early trial results — even positive Phase 2 data — frequently fail to be confirmed in larger Phase 3 trials. The authors themselves note that \"unexpected negative results from potential therapies that showed promise in earlier stages of drug development\" have already occurred in this field.\u003c\/li\u003e\n  \u003cli\u003eThe prevalence estimates for NAFLD, NASH, and ALD are based on population studies that carry their own uncertainties. ALD in particular is underreported because of social stigma, and NASH is underdiagnosed because it is often silent and up to 30% of affected patients have normal liver enzymes.\u003c\/li\u003e\n  \u003cli\u003eThe article's discussion of bile acid pathways is incomplete in the source text, so some details of that section could not be fully translated.\u003c\/li\u003e\n  \u003cli\u003eMost of the clinical trial data presented come from relatively short-term studies (12 to 36 weeks). Because detecting a 1-stage change in fibrosis can take up to 7 years, long-term efficacy and safety remain unknown for all of these agents.\u003c\/li\u003e\n  \u003cli\u003eFinally, the review was written before the full impact of the COVID-19 pandemic on clinical trials, alcohol consumption patterns, and liver disease progression could be assessed.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"recommendations\"\u003eRecommendations for Patients\u003c\/h2\u003e\n\n\u003cp\u003eBased on the information in this review, patients and their families may wish to consider the following steps:\u003c\/p\u003e\n\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAsk about a liver fibrosis assessment.\u003c\/strong\u003e If you have been told you have fatty liver, ask your doctor about non-invasive tests such as FIB-4, NAFLD fibrosis score, or vibration controlled transient elastography (VCTE) to estimate your fibrosis stage. Advanced fibrosis (stage F3\/F4) is the strongest predictor of liver-related and all-cause death, so knowing your stage matters for monitoring and treatment decisions.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDo not ignore NAFLD just because your liver enzymes are normal.\u003c\/strong\u003e Up to 30% of patients with NASH have normal liver enzymes. If you have risk factors such as obesity, type 2 diabetes, or metabolic syndrome, speak with your doctor about whether additional evaluation is warranted.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eConsider clinical trials cautiously but optimistically.\u003c\/strong\u003e With over 100 registered NASH trials, there are more opportunities than ever to participate in research. However, the high placebo response rate documented in this review means that early enthusiasm for a new drug should be tempered until larger, late-stage results are available.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFor alcohol-related liver disease, abstinence remains the most effective treatment.\u003c\/strong\u003e The review states this directly: \"Alcohol abstinence remains the most effective therapy to reverse ALD.\" If you have ALD or are at risk for it, talk to a healthcare provider about alcohol reduction or cessation support programs.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eWatch for combination therapies.\u003c\/strong\u003e Because even effective drugs improve NASH in only a minority of patients, the future likely belongs to combination treatments that target inflammation, fat accumulation, and fibrosis simultaneously. Patients should ask their doctors about whether any of the emerging drugs discussed in this article — or similar agents — might be appropriate for their specific situation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePay attention to the cardiovascular connection.\u003c\/strong\u003e NAFLD and ALD both increase the risk of cardiovascular disease, and the thyroid receptor beta agonists discussed here significantly improved lipid profiles (LDL, triglycerides, lipoprotein(a), and apolipoprotein B). Patients with fatty liver should have their cardiovascular risk factors assessed and managed aggressively, not just their liver enzymes.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eWhat is the difference between NAFLD and alcohol-related liver disease?\u003c\/h3\u003e\n\u003cp\u003eNAFLD is fatty liver not caused by alcohol; ALD is caused by alcohol. Both can cause fatty liver, inflammation, scarring, cirrhosis, and liver cancer. If you have both, progression is faster. Together they are the most common reasons for liver transplantation in the United States.\u003c\/p\u003e\n\u003ch3\u003eWhy are there so many new clinical trials for NASH right now?\u003c\/h3\u003e\n\u003cp\u003eAfter hepatitis C became curable, drug companies turned to NASH. Currently over 100 clinical trials are registered. This is driven by rising obesity and NAFLD, plus strong links to type 2 diabetes. Researchers are testing many drugs that target fat, inflammation, and fibrosis.\u003c\/p\u003e\n\u003ch3\u003eWhat is the placebo response in NASH trials and why does it matter?\u003c\/h3\u003e\n\u003cp\u003eIn a meta-analysis of 39 trials, 25% of patients taking placebo improved their NAFLD Activity Score by 2 or more points, and 21% showed improved fibrosis. This likely reflects lifestyle changes patients make when joining a trial. It makes proving that a drug truly works more difficult.\u003c\/p\u003e\n\u003ch3\u003eShould I worry about NASH if my liver enzymes are normal?\u003c\/h3\u003e\n\u003cp\u003eYes, up to 30% of patients with NASH have completely normal liver enzymes on routine blood tests. If you have risk factors such as obesity, type 2 diabetes, or metabolic syndrome, ask your doctor whether additional evaluation, like a fibrosis assessment, is appropriate. Normal liver enzymes do not rule out NASH.\u003c\/p\u003e\n\u003ch3\u003eWhat should I ask my doctor if I have fatty liver?\u003c\/h3\u003e\n\u003cp\u003eAsk about a liver fibrosis assessment using non-invasive tests such as FIB-4, NAFLD fibrosis score, or vibration controlled transient elastography (VCTE). Advanced fibrosis (stage F3\/F4) is the strongest predictor of liver-related and all-cause death, so knowing your stage helps guide monitoring and treatment decisions.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eOriginal article title:\u003c\/strong\u003e Basic science to clinical trials in non-alcoholic fatty liver disease\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthors:\u003c\/strong\u003e Amon Asgharpour, Amreen Dinani, Scott L. Friedman (all authors contributed equally to the conception and design; Asgharpour and Dinani share first authorship)\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eAffiliation:\u003c\/strong\u003e Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USA\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eJournal:\u003c\/strong\u003e Translational Gastroenterology and Hepatology, 2021; Volume 6, Article 5\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePublication details:\u003c\/strong\u003e Received August 27, 2019; Accepted January 17, 2020; Published January 5, 2021. DOI: 10.21037\/tgh.2020.01.04\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eNote:\u003c\/strong\u003e This patient-friendly article is based on peer-reviewed research. It is intended for educational purposes and does not replace individualized medical advice from a qualified healthcare provider.\u003c\/p\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47405674135708,"sku":null,"price":0.0,"currency_code":"EUR","in_stock":true}],"url":"https:\/\/diagnosticdetectives.fr\/products\/new-treatments-for-fatty-liver-disease-and-alcohol-related-liver-disease-a-patients-guide-to-the-science-behind-the-clinical-trials","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}